Form 4: Ionis Pharmaceuticals CEO Brett Monia Reports Stock Transactions

Ionis Pharmaceuticals CEO Brett Monia acquired shares through vesting of restricted stock units and sold shares to cover tax obligations.

Summary

• Brett Monia, CEO of Ionis Pharmaceuticals, acquired 73,448 shares of common stock on January 15, 2025, through the vesting of restricted stock units.
• On January 16, 2025, Mr. Monia sold 33,445 shares of common stock at a weighted average price of $32.634 per share to cover tax withholding obligations.
• Mr. Monia was also granted 169,950 performance restricted stock units (PRSUs) and 129,395 restricted stock units (RSUs) on January 15, 2025.
• The PRSUs may vest based on the company's total shareholder return compared to a peer group over a three-year period, with a maximum of 200% of the target number vesting.
• The RSUs vest in four equal annual installments.

Sentiment

Score: 7

Explanation: The document reflects standard executive stock transactions, with a positive aspect of vesting and a neutral aspect of tax-related sales. The sentiment is moderately positive due to the alignment of management interests with shareholders through equity compensation.

Positives

• The vesting of restricted stock units indicates that performance targets were likely met.
• The grant of additional performance-based and time-based restricted stock units aligns management's interests with shareholders.

Negatives

• The sale of 33,445 shares, while for tax purposes, could be perceived negatively by some investors.

Risks

• The vesting of performance restricted stock units is contingent on the company's performance relative to its peers, which introduces uncertainty.
• The actual number of PRSUs that will vest may be anywhere from zero to the maximum stated.

Future Outlook

The performance restricted stock units will vest based on the company's total shareholder return over the next three years, which is a key factor for future executive compensation.

Management Comments

• The sale of shares was an automatic sale to cover required tax withholding obligations.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

Industry Context

This is a standard Form 4 filing, which is common for publicly traded companies when executives trade company stock. It provides transparency into executive compensation and ownership.

Comparison to Industry Standards

• The use of restricted stock units and performance-based restricted stock units is a common practice in the biotechnology industry to align executive compensation with company performance and shareholder value.
• Many biotech companies use similar vesting schedules and performance metrics for their equity compensation plans.
• The sale of shares to cover tax obligations is also a standard practice among executives who receive equity compensation.

Stakeholder Impact

• Shareholders may view the vesting of restricted stock units positively, as it indicates that performance targets were likely met.
• The sale of shares to cover tax obligations is a standard practice and should not have a significant impact on stakeholders.

Next Steps

• The performance of the company will be monitored over the next three years to determine the vesting of the performance restricted stock units.
• The restricted stock units will continue to vest in four equal annual installments.

Key Dates

Keywords

Ionis Pharmaceuticals, Brett Monia, stock transaction, restricted stock units, performance restricted stock units, insider trading, equity compensation, vesting